Accounts Payable

9 Months Ended

Sep. 30, 2019

Accounts Payable

Accounts Payable

5.Accounts Payable

As of September 30, 2019, Current Liabilities included accounts payable of $0.5 million, comprised primarily of amounts owed for external research expenses related to manufacturing and preclinical studies of $0.4 million and $0.1 million, respectively. As of December 31, 2018, Current Liabilities included accounts payable of $0.6 million, comprised primarily of preclinical expenses of $0.2 million, amounts owed to the Company’s clinical research organizations for our clinical trials for prexigebersen in AML and CML of $0.1 million, an annual license maintenance fee of $0.1 million, manufacturing costs of $0.1 million and other payables of $0.1 million.